NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free DVAX Stock Alerts $11.28 -0.06 (-0.53%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$11.18▼$11.4550-Day Range$10.73▼$12.3252-Week Range$10.48▼$15.15Volume1.61 million shsAverage Volume2.03 million shsMarket Capitalization$1.48 billionP/E Ratio188.00Dividend YieldN/APrice Target$25.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Dynavax Technologies alerts: Email Address Dynavax Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside122.0% Upside$25.33 Price TargetShort InterestBearish16.34% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment1.44Based on 5 Articles This WeekInsider TradingSelling Shares$43,127 Sold Last QuarterProj. Earnings Growth108.33%From $0.12 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.57 out of 5 starsMedical Sector93rd out of 913 stocksPharmaceutical Preparations Industry33rd out of 430 stocks 3.4 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDynavax Technologies has only been the subject of 1 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.34% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 5.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 3.6 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dynavax Technologies this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,127.00 in company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 108.33% in the coming year, from $0.12 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 190.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 135.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 190.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 134.89.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. About Dynavax Technologies Stock (NASDAQ:DVAX)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More DVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Stock News HeadlinesJune 4, 2024 | insidertrades.comDynavax Technologies Co. (NASDAQ:DVAX) Director Francis Cano Sells 3,615 SharesJune 18 at 5:08 AM | americanbankingnews.comDynavax Technologies Co. (NASDAQ:DVAX) Short Interest Down 5.8% in MayJune 18, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.May 28, 2024 | prnewswire.comDynavax to Present at Upcoming Investor ConferencesMay 14, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B Regimen for Adults on Hemodialysis in the U.S.May 14, 2024 | markets.businessinsider.comHold Rating on Dynavax Amidst FDA Setback and Long-term Profitability FocusMay 14, 2024 | markets.businessinsider.comDynavax Receives FDA's CRL Regarding Four-Dose Heplisav-B Vaccine For Hemodialysis PatientsMay 14, 2024 | msn.comFDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis PatientsJune 18, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.May 14, 2024 | finance.yahoo.comUPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccineMay 14, 2024 | reuters.comUS FDA declines to approve expanded use of Dynavax's hepatitis B vaccineMay 14, 2024 | prnewswire.comDynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.May 11, 2024 | finance.yahoo.comAnalysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter ResultsMay 10, 2024 | finance.yahoo.comDynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...May 10, 2024 | finance.yahoo.comDynavax Technologies First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | seekingalpha.comDynavax: HEPLISAV-B Growth Up, Pipeline UncertainMay 9, 2024 | insidermonkey.comDynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 9, 2024 | fool.comDynavax Technologies (DVAX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comDynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...May 8, 2024 | investorplace.comDVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comDynavax Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | markets.businessinsider.comDynavax Technologies earnings preview: what Wall Street is expectingMay 7, 2024 | msn.comDynavax Q1 2024 Earnings PreviewApril 30, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In May 2024April 24, 2024 | finance.yahoo.comDynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 9, 2024 | stocknews.com3 Biotech Buys Under $15See More Headlines Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/18/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees408Year Founded1996Price Target and Rating Average Stock Price Target$25.33 High Stock Price Target$29.00 Low Stock Price Target$20.00 Potential Upside/Downside+122.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio190.17 Forward P/E Ratio95.08 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins3.91% Pretax Margin3.33% Return on Equity1.52% Return on Assets0.95% Debt Debt-to-Equity Ratio0.36 Current Ratio15.20 Quick Ratio14.10 Sales & Book Value Annual Sales$232.28 million Price / Sales6.43 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book2.37Miscellaneous Outstanding Shares130,890,000Free Float126,991,000Market Cap$1.49 billion OptionableOptionable Beta1.20 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Ryan Spencer (Age 46)CEO, Interim CFO & Director Comp: $1.49MMr. David F. Novack (Age 62)President & COO Comp: $1.01MDr. Robert Janssen M.D. (Age 70)Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Comp: $861.52kMs. Kelly MacDonald (Age 40)Senior VP & CFO (Leave of Absence) Comp: $788.55kMr. Justin BurgessChief Accounting Officer & ControllerMr. Jeff P. Coon (Age 61)Senior VP & Chief Human Resources Officer Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsMr. John L. Slebir (Age 58)Senior VP & General Counsel Mr. Donn CasaleSenior VP & Chief Commercial OfficerDr. Dong YuSenior Vice President of Vaccine ResearchMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAUroGen PharmaNASDAQ:URGNPuma BiotechnologyNASDAQ:PBYIG1 TherapeuticsNASDAQ:GTHXMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsFrancis CanoSold 3,615 sharesTotal: $43,126.95 ($11.93/share)Boston PartnersBought 23,507 shares on 5/28/2024Ownership: 0.018%Burney Co.Sold 135,348 shares on 5/22/2024Ownership: 0.306%Swedbank ABBought 301,400 shares on 5/21/2024Ownership: 0.230%Comerica BankSold 7,169 shares on 5/17/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions DVAX Stock Analysis - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price target for 2024? 4 analysts have issued 1 year price targets for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $29.00. On average, they predict the company's share price to reach $25.33 in the next twelve months. This suggests a possible upside of 122.0% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2024? Dynavax Technologies' stock was trading at $13.98 at the beginning of the year. Since then, DVAX stock has decreased by 18.4% and is now trading at $11.41. View the best growth stocks for 2024 here. Are investors shorting Dynavax Technologies? Dynavax Technologies saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 21,390,000 shares, a decline of 5.8% from the May 15th total of 22,700,000 shares. Based on an average trading volume of 2,100,000 shares, the short-interest ratio is currently 10.2 days. View Dynavax Technologies' Short Interest. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DVAX earnings forecast. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The biopharmaceutical company had revenue of $50.79 million for the quarter, compared to analysts' expectations of $51.98 million. Dynavax Technologies had a trailing twelve-month return on equity of 1.52% and a net margin of 3.91%. What ETFs hold Dynavax Technologies' stock? ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco S&P SmallCap Health Care ETF (PSCH) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.18%), Kynam Capital Management LP (3.24%), Blair William & Co. IL (1.84%), Mizuho Markets Americas LLC (0.65%), Principal Financial Group Inc. (0.59%) and Essex Investment Management Co. LLC (0.31%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DVAX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredThe Hidden Anchor Investment of the Elite RevealedThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because sav...Colonial Metals | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
